20% Off Everything · No Code NeededThird-Party Tested at the Source LabShips Within 1 Business Day · TrackedU.S. Sourced · U.S. ShippedFree 2-Day Shipping at $1,000 and Over≥99% Purity — HPLC + Mass SpecLot-Matched Certificate on File for Every Lot We Ship20% Off Everything · No Code NeededThird-Party Tested at the Source LabShips Within 1 Business Day · TrackedU.S. Sourced · U.S. ShippedFree 2-Day Shipping at $1,000 and Over≥99% Purity — HPLC + Mass SpecLot-Matched Certificate on File for Every Lot We Ship
For Laboratory & Research Use Only — Not for Human or Veterinary Use
All ProductsGLP-1 & MetabolicResearch PeptidesPeptide BlendsNasal SpraysDissolving StripsBioregulatorsResearch BundlesLab Supplies Search
Third-Party Tested · Certificate on FileBest Seller
LY3437943: GLP-1 / GIP / glucagon triple receptor agonist for laboratory research. Third-party tested, 99%+ purity, COA available. Sizes: 10 mg, 20 mg, 30 mg, 48 mg, 60 mg.
Size
$105.00$84.00/ 10 mg · USD20% off, no code
Certificate on file. Lot RETA10-0803 · Bioviridian · 99.83% purity by HPLC · identity by LC-MS/MS · tested Aug 17, 2026. Full lot results →
Printed minimum ≥ 99.0 % · measured on this lot 99.83 % · content 10.61 mg · stated 10 mg
Our guaranteeA lot that fails its own published specification is refunded in full, opened or not. Damaged, wrong or short items are replaced at our cost: send a photo within 72 hours of delivery. Full policy
  • Lot-matched certificate of analysis, identity and purity by HPLC and mass spec
  • Ships within 1 business day from the U.S., tracked, in protective packaging
  • Research use only. Not for human or animal use
1
SKU RT-10
Shipping
  • Ships within 1 business day, tracked, protective packaging
  • 2-Day $12.99, free at $1,000 and over
  • Overnight $250
  • Certificate of analysis available on request
  • ≥99% purity specification, HPLC & mass-spec verified at source
  • Ships from a U.S. facility within 1 business day
  • Secure card checkout on our payment partner's page, 20% already in the total

Complete your setup

Lyophilized peptides need bacteriostatic water and sterile lab supplies to reconstitute. Add the essentials in one click.

HG-RTA-3HG-RTA-3In your order
Total for 2 items, 20% off, no code$135.00 $108.00

LY3437943 is a synthetic 39-residue triple receptor agonist engaging the GIP, GLP-1, and glucagon receptors at once. A 2022 paper in Cell Metabolism examines how combining glucagon receptor activity with dual incretin signaling affects glucose control and body weight in obese mouse models, extending the dual-agonist pharmacology studied for related compounds.

LY3437943 is a synthetic 39-amino-acid peptide engineered to act on three receptors at once: GLP-1, GIP and glucagon. By engaging all three incretin and glucagon pathways, it is used to model how combined receptor signaling influences energy balance in preclinical systems.

Common research applications include:

  • Metabolic and energy-expenditure models
  • Incretin receptor pharmacology
  • Comparative studies against single- and dual-agonist peptides

Specifications

  • Class: GLP-1 / GIP / glucagon triple receptor agonist
  • Form: lyophilized powder in a sealed glass vial
  • Available sizes: 10 mg, 20 mg, 30 mg, 48 mg, 60 mg
  • Purity: verified at 99% or higher by HPLC, identity confirmed by mass spectrometry
  • Testing: every lot is third-party tested, with a lot-matched Certificate of Analysis available on request
  • supplied by a U.S. lab
  • Storage: keep sealed, cool, dry and away from light; refrigerate after reconstitution

For laboratory research use only. This product is not for human or veterinary use, is not a drug, food or cosmetic, and is not intended to diagnose, treat, cure or prevent any disease.

What the Literature Studies

Coskun and colleagues described LY3437943's discovery pharmacology in a 2022 paper in Cell Metabolism, naming it a triple agonist at the glucagon receptor, GIP receptor, and GLP-1 receptor. In vitro signaling assays showed balanced glucagon and GLP-1 receptor activity with comparatively higher GIP receptor activity. In obese mice, administration decreased body weight and improved glycemic control; the paper attributes the body weight effect to glucagon-receptor-driven increases in energy expenditure adding to the calorie-intake reduction already associated with GIP and GLP-1 receptor signaling. A related 2026 paper by Briand and colleagues in Obesity reports comparable metabolic findings for LY3437943 across diet-induced obese mouse and hamster models, extending the triple-agonist mechanism to additional rodent species.

Specification and Handling

This lot is a 39-residue triple agonist with Aib residues, alpha-methyl-leucine, and a Lys-conjugated (AEEA)-gamma-Glu-C20 diacid, C-terminal serinamide, full sequence per the certificate of analysis. CAS number is 2381089-83-2. Supplied as a lyophilized powder, purity verified at 99% or greater by HPLC, identity confirmed by mass spectrometry, with the certificate of analysis for the lot available on request; this catalog's specification sheet does not list a molecular formula or weight for this particular lot. The powder is soluble in bacteriostatic water. Sealed vials are stored at -20°C, protected from light and moisture, and reconstituted solution is refrigerated at 2-8°C and split into single-use aliquots.

Buying Notes

LY3437943 is available in 10 mg, 20 mg, 30 mg, 48 mg, and 60 mg lyophilized vials, covering a broad range of total peptide quantities for different research scales and budgets across this catalog's metabolic research category. The certificate of analysis for each lot reports HPLC purity and mass spectrometry identity confirmation for this triple-agonist sequence on that specific lot and batch. For receptor-class and structural comparisons, see the HG RTA 3 research page for handling detail on this specific lot, and the LY3437943 RESEARCH LITERATURE OVERVIEW article for a broader summary of the published pharmacology behind this triple-agonist compound.

Purity≥99% by HPLC · COA available
CAS Number2381089-83-2
Molecular FormulaC256H392N64O79
Molecular Weight4731.2 g/mol
Amino Acid Count39
Sequence39-residue GIP/GLP-1/glucagon triple agonist with Aib residues, α-Me-Leu, and a Lys-conjugated (AEEA)-γGlu-C20 diacid; C-terminal serinamide (per COA)
SynonymsGGG tri-agonist; LY3437943
Physical FormLyophilized powder
SolubilitySoluble in bacteriostatic water; consult the product COA for specific solvent recommendations.
StorageStore lyophilized at -20°C; protect from light and moisture. Reconstitute with bacteriostatic water; refrigerate reconstituted solution at 2-8°C.
Documentation

Lots on file for HG-RTA-3

One row per size. Purity by RP-HPLC, measured content against the stated amount, and the date the independent laboratory issued the certificate. Printed minimum ≥ 99.0 %.

SizeLotPurity (RP-HPLC)Measured content vs labelCertificate dateResults
10 mgRETA10-080399.83 %10.61 mg · stated 10 mgAug 17, 2026Lot results →
20 mgRETA20-080399.79 %20.22 mg · stated 20 mgAug 17, 2026Lot results →
30 mgRETA30-080399.83 %30.94 mg · stated 30 mgAug 17, 2026Lot results →
48 mgRETA48-061699.9 %48.16 mg · stated 48 mgJun 25, 2026Lot results →
60 mgRETA60-080399.85 %61.26 mg · stated 60 mgAug 17, 2026Lot results →
Answers

Frequently Asked Questions

What three receptors does LY3437943 engage, according to the 2022 paper?

The Coskun 2022 Cell Metabolism paper describes LY3437943 as a triple agonist at the glucagon receptor, GIP receptor, and GLP-1 receptor. In vitro assays in that paper found balanced glucagon and GLP-1 receptor activity with higher GIP receptor activity.

Why add a glucagon receptor component to an incretin agonist?

The 2022 paper attributes additional body weight effects in obese mice to glucagon-receptor-driven increases in energy expenditure, on top of the calorie-intake reduction already linked to GIP and GLP-1 receptor signaling. This is the stated rationale for the triple-agonist design.

Has LY3437943 been studied in species beyond mice?

Yes. A 2026 paper by Briand and colleagues in Obesity reports comparable metabolic findings across diet-induced obese mouse and hamster models, extending the rodent data beyond the original mouse-only pharmacology.

Why does the catalog listing not show a molecular formula for LY3437943?

That field is not populated on this product's specification sheet. CAS number 2381089-83-2 and the certificate of analysis for the specific lot are the identity references provided instead.

How does LY3437943's design relate to LY3298176's?

LY3437943 adds glucagon receptor activity on top of the GIP and GLP-1 receptor engagement that LY3298176 already has. The comparison guide on this site covers how the published structures and receptor-activity profiles differ between the two.

Is HG-RTA-3 third-party tested?

Yes. Every lot is tested for identity and purity at the source lab by HPLC and mass spectrometry against a ≥99% purity specification. The lot-matched certificate of analysis is on file and shown on this page.

Can I see the Certificate of Analysis before buying?

Yes. The certificate on file for the current lot is linked above, documenting identity, purity, and analytical results. Ask us for any other lot.

What does 'Research Use Only' mean?

This product is supplied strictly for laboratory and research use only (RUO). It is not a drug, food, supplement, or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease, or for human or veterinary consumption.

How is it shipped and stored?

Orders ship within 1 business day from our U.S. facility with tracking. Store the lyophilized material at −20°C, protected from light and moisture.

Research Library

Learn more about HG-RTA-3

HG-RTA-3 — molecular profile & reference →NN9535 vs LY3298176 vs LY3437943Reconstitution calculator
Further reading

From the research blog

More from this category

GLP-1 & Metabolic

← Back to GLP-1 & MetabolicAll Categories